Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Payers' Guide
Specialty Drugs Top the Trends in the 2014 Pipeline
Read More
Payers' Guide
Abraxane (nab-Paclitaxel) Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer
Read More
Payers' Guide
Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension
Read More
Payers' Guide
Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation
Read More
Payers' Guide
Anoro Ellipta (Umeclidinium/Vilanterol): First Dual Long-Acting Inhaler for Long-Term Maintenance Treatment of COPD
Read More
Payers' Guide
Botox (OnabotulinumtoxinA) Now FDA Approved for Overactive Bladder
Read More
Payers' Guide
Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Read More
Payers' Guide
Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder
Read More
Payers' Guide
Gazyva (Obinutuzumab) for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Read More
Payers' Guide
Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Read More
149
150
151
152
153
154
155
Page 152 of 244
Results 1511 - 1520 of 2434